Cargando…
Serum Mass Spectrometry Proteomics and Protein Set Identification in Response to FOLFOX-4 in Drug-Resistant Ovarian Carcinoma
SIMPLE SUMMARY: A mass spectrometry (MS) proteomics and molecular pathway study was applied to serum samples of patients with ovarian serous carcinoma administered the FOLFOX-4 drug combination protocol, before the second cycle of therapy. This exploratory study aimed at identifying a protein panel...
Autores principales: | D’Arca, Domenico, Severi, Leda, Ferrari, Stefania, Dozza, Luca, Marverti, Gaetano, Magni, Fulvio, Chinello, Clizia, Pagani, Lisa, Tagliazucchi, Lorenzo, Villani, Marco, d’Addese, Gianluca, Piga, Isabella, Conteduca, Vincenza, Rossi, Lorena, Gurioli, Giorgia, De Giorgi, Ugo, Losi, Lorena, Costi, Maria Paola |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856519/ https://www.ncbi.nlm.nih.gov/pubmed/36672361 http://dx.doi.org/10.3390/cancers15020412 |
Ejemplares similares
-
Proteomic and Bioinformatic Studies for the Characterization of Response to Pemetrexed in Platinum Drug Resistant Ovarian Cancer
por: Severi, Leda, et al.
Publicado: (2018) -
A Peptidic Thymidylate-Synthase Inhibitor Loaded on Pegylated Liposomes Enhances the Antitumour Effect of Chemotherapy Drugs in Human Ovarian Cancer Cells
por: Marverti, Gaetano, et al.
Publicado: (2020) -
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer
por: Conteduca, Vincenza, et al.
Publicado: (2018) -
Structural Bases for the Synergistic Inhibition of Human Thymidylate Synthase and Ovarian Cancer Cell Growth by Drug Combinations
por: Pozzi, Cecilia, et al.
Publicado: (2021) -
Repurposing of Drugs Targeting YAP-TEAD Functions
por: Elisi, Gian Marco, et al.
Publicado: (2018)